Summary
In an effort to improve the treatment of patients with refractory or recurrent lymphoma, we developed a protocol using cis-platinum combined with two other agents of known efficacy in these disorders but with differing side effects: VP-16 and MGBG. Twenty-six eligible patients were treated with this regimen. There were 15 men and 11 women with a median age of 54 years (22–73), and performance status of 1 (0–3). Their diagnoses were Hodgkin's disease 5 and non-Hodgkin's lymphoma [NHL] 21 which included 11 with diffuse histocytic lymphoma [DHL]. The median number of chemotherapy regimens was 2 (1–5); 12 also received radiotherapy. Twenty patients are evaluable for response: 15 NHL and 5 Hodgkin's disease. Three patients, all of whom had DHL entered complete remission (20%) with a median time to treatment failure of 7 1/2 months. Six NHL (40%) and one Hodgkin's disease (20%) patients entered a partial remission. There were three early deaths: one due to progressive disease, one to acute respiratory failure, and one with disease status undocumented. Toxicity included leukopenia, thrombocytopenia, anorexia, nausea, vomiting, stomatitis, alopecia, renal failure, profound peripheral neuropathy, and hypersensitivity vasculitis. Treatment was stopped because of the latter two. These agents are non-crossresistant with doxorubicin-containing regimens. The drugs are possibly synergistic and modestly active with moderate to severe toxicity.
Similar content being viewed by others
References
Rossof AH, Coltman Jr CA, Jones SE, Talley RW: Phase II Evaluation of Cis-Dichlorodiammineplatinum (II) in Lymphomas: A Southwest Oncology Group Study. Cancer Treat Rep 63:1605–08, 1979
Cavalli F, Junghi WF, Nissen NI, Pajak TF, Coleman M, Holland JF: Phase II Trial of Cis-Dichlorodiammineplatinum (II) in Advanced Malignant Lymphoma. A Study of the Cancer and Acute Leukemia Group B. Cancer 48: 1927–30, 1981
Judson IR, Wiltshaw E: Cis-Dichlorodiammineplatinum (Cis-Platinum) and Etoposide (VP-16) in Malignant Lymphoma — an Effective Salvage Regimen. Cancer Chemother Pharmacol 14:258–61, 1981
Kaplan RS, Budman D, Gottlieb A, Anderson J: Phase II Trial of Etoposide (VP-16) and Cisplatin (DDP) in Refractory Non-Hodgkin's Lymphomas (NHL). A CALGB Study. Proc Am Soc Clin Oncol 4: 203, 1985 (Abstr)
Kroner T, Obrecht JP, Junghi WF: Etoposide as Single Agent and in Combination with Cis-Platinum for Malignant Lymphomas. Cancer Treat Rev 9 (Supple A) 39–43, 1982
Von Heyden HW, Scherpe A, Nagel GA: Cis-Dichlorodiammineplatinum (II) (Cis-Platinum) and Etoposide for Patients with Refractory Lymphomas. Cancer Treat Rev 9 (Supple A) 45–52, 1982
Fosser VP, Salvagno L, Segati R, Pappagallo GL, Ferrazzi E, Sileni VC, Fiorentino MV: Cis-Dichlorodiammineplatinum (II), VP16–213 and Prednisone (DVP Regimen) in the Treatment of Pretreated Advanced Malignant Lymphomas. Tumori 68:515–8, 1982
Williams SF, Ultman JE, Gaynor E, Watson S: Management of Advanced, Resistant Hodgkin's Disease and Non-Hodgkin's Lymphoma: A Phase II Study. Cancer Treat Rep 70:1033–4, 1986
Silverman L, Jones R, Norton L, Cuttner J, Malamud S, Holland JF: Combination Chemotherapy for Refractory Lymphoma with Cytosine Arabinoside (A) Cisplatin (P) and Etoposide (E): APE. Proc Am Soc Clin Oncol 3:246, 1984 (Abstr)
Dana BW, Jones SE, Coltman C, Stuckey WJ: Salvage Treatment of Unfavorable Non-Hodgkin's Lymphoma with Cisplatin, Amsacrine, and Mitoguazone: A Southwest Group Pilot Study. Cancer Treat Rep 70:291–2, 1986
Camacho F, Oken M, O'Connell M, Perri R, Phillips V, Wiernik P: Salvage Therapy in Patients (Pts) with Refractory Malignant Lymphoma Using Methylglyoxal Bisguanylhydrazone (MGBG), Vindesine (VDS) and Cisplatinum (CPPD). Proc Am Soc Clin Oncol 3:242, 1984 (Abstr)
Tseng Jr A, Jacobs C, Coleman C, Horning S, Lewis B, Rosenberg S: Treatment of Refractory Non-Hodgkin's Lymphomas of Unfavorable Histology with Tenoposide (VM-26), Cytosine Arabinoside (Ara-C) and Cisplatin. Proc Am Soc Clin Oncol 4:203, 1985 (Abstr)
Spiers ASD, Weens JH, Parkinson DR, O'Connell MJ: Treatment of Refractory Lymphomas with BCNU, Bleomycin, VM-26, Dexamethasone and Cisplatin (BBVDD Regimen). Proc Am Soc Clin Oncol 3:237, 1984 (Abstr)
Liepman MK, Wheeler RH, Zuckerman KS, LoBuglio AF: Combination Chemotherapy of Refractory Lymphoma with Cis-Dichlorodiammineplatinum, Vinblastine and Bleomycin. Cancer 50:2736–39, 1982
Corder MP, Clamon GH: Salvage Therapy of Aggressive Non-Hodgkin's Lymphoma with a Combination of Vinblastine, Bleomycin and Cisplatin. Cancer 54:202–6, 1984
Velasquez W, Caranillas F, McLaughlin P, Plunkett W, Hagemeister F, Swan F, Freireich EJ: Combination of Cisplatin-Ara-C and Decadron in Relapsing Lymphoma. Proc Am Soc Clin Oncol 5: 191, 1986 (Abstr)
Radice PA, Bunn Jr PA, Ihde DC: Therapeutic Trials with VP-16–213 and VM 26: Active Agents in Small Cell Lung Cancer, Non-Hodgkin's Lymphoma and Other Malignancies. Cancer Treat Rep 63:1231–39, 1979
Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Kennedy BJ, Ellison RE, Silver RT, Weiss RB, Cuttner J, Falkson G, Kung F, Bergevin PR, Holland JF: Clinical Trial of VP/16–213 (NSC141540) I.V. Twice Weekly in Advanced Neoplastic Disease. A Study by the Cancer and Leukemia Group B. Cancer 45:232–35, 1980
Issel BF, Crooke ST: Etoposide (VP-16–213). Cancer Treat Rev 6:107–24, 1979
Freireich E, Frei III E, Karon M: Methylglyoxal Bis (guanylhydrazone): A New Active Agent Against Acute Myelocytic Leukemia. Cancer Chemother Rep 16:183–86, 1962
Bender RA, Anderson T, Fisher RI, Young RC: Activity of the Epipodophyllotoxin VP-16 in the Treatment of Combination Chemotherapy-Resistant Non-Hodgkin Lymphoma. Amer J Hematol 5:203–09, 1978
Knight III WAT, Fabian C, Constanzi JJ, Jones SE, Coltman Jr CA: Methyl-glyoxal Bis Guanylhydrazone (Methyl-gag, MGBG) in Lymphoma and Hodgkin's Disease. Invest New Drugs 1:235–7, 1983
Warrell RP, Lee BJ, Kempin SJ, Lacher MJ, Straus DJ, Young CW: Effectiveness of Methyl-Gag (Methylglyoxal-Bis [Guanylhydrazone]) in Patients with Advanced Malignant Lymphoma. Blood 57:1011–14, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dabich, L., Liepman, M.K. Cisplatin, VP-16-213 and MGBG (Methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study. Invest New Drugs 6, 231–237 (1988). https://doi.org/10.1007/BF00175405
Issue Date:
DOI: https://doi.org/10.1007/BF00175405